These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 12904118)

  • 21. FDA turns to electronic "sentinel" to flag prescription drug safety problems.
    Kuehn BM
    JAMA; 2008 Jul; 300(2):156-7. PubMed ID: 18612108
    [No Abstract]   [Full Text] [Related]  

  • 22. Towards Drug Safety Surveillance and Pharmacovigilance: Current Progress in Detecting Medication and Adverse Drug Events from Electronic Health Records.
    Liu F; Jagannatha A; Yu H
    Drug Saf; 2019 Jan; 42(1):95-97. PubMed ID: 30649734
    [No Abstract]   [Full Text] [Related]  

  • 23. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
    Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
    Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strengthening standards, transparency, and collaboration to support medicine evaluation: Ten years of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP).
    Kurz X; Perez-Gutthann S;
    Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):245-252. PubMed ID: 29327451
    [No Abstract]   [Full Text] [Related]  

  • 25. The monitoring medicines project: a multinational pharmacovigilance and public health project.
    Pal SN; Olsson S; Brown EG
    Drug Saf; 2015 Apr; 38(4):319-28. PubMed ID: 25829215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. European pharmacovigilance legislation: has it led to implementation of pharmacovigilance inspections?
    Bleumink GS; in't Veld BA; Stricker BH
    Pharmacoepidemiol Drug Saf; 2001; 10(4):339-40. PubMed ID: 11760496
    [No Abstract]   [Full Text] [Related]  

  • 27. Pharmacovigilance: Importance, concepts, and processes.
    Kumar A
    Am J Health Syst Pharm; 2017 Apr; 74(8):606-612. PubMed ID: 28235869
    [No Abstract]   [Full Text] [Related]  

  • 28. [Drug surveillance within the pharmaceutical industry: present and future].
    Soto J; Sacristán JA; Alsar MJ; Galende I
    Med Clin (Barc); 1996 May; 106(17):665-9. PubMed ID: 8691914
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmacovigilance in Europe: Place of the Pharmacovigilance Risk Assessment Committee (PRAC) in organisation and decisional processes.
    Laroche ML; Batz A; Géniaux H; Féchant C; Merle L; Maison P
    Therapie; 2016 Apr; 71(2):161-9. PubMed ID: 27080834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Geographical variation in reporting Interstitial Lung Disease as an adverse drug reaction: findings from an European Medicines Agency analysis of reports in EudraVigilance.
    Pinheiro L; Blake K; Januskiene J; Yue QY; Arlett P
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):705-12. PubMed ID: 27004571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What do stakeholders think about pharmacovigilance?
    Edwards IR; Graedon T
    Drug Saf; 2010 Aug; 33(8):619-21. PubMed ID: 20635819
    [No Abstract]   [Full Text] [Related]  

  • 32. Assessment of the impact of scheduled postmarketing safety summary analyses on regulatory actions.
    Sekine S; Pinnow EE; Wu E; Kurtzig R; Hall M; Dal Pan GJ
    Clin Pharmacol Ther; 2016 Jul; 100(1):102-8. PubMed ID: 26853718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The reorganisation of European pharmacovigilance. Part 2. From spontaneous reports to agency reviews and decisions.
    Prescrire Int; 2015 Feb; 24(157):50-4. PubMed ID: 25802924
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges.
    Issa AM
    Pharmacogenomics; 2003 Sep; 4(5):647-55. PubMed ID: 12943471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacovigilance Programme of India: Recent developments and future perspectives.
    Kalaiselvan V; Thota P; Singh GN
    Indian J Pharmacol; 2016; 48(6):624-628. PubMed ID: 28066097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Methods for drug safety monitoring: yesterday, today, tomorrow].
    Nazimkin KE; Ovchinnikova EA; Zhuravleva MV
    Antibiot Khimioter; 2007; 52(7-8):41-52. PubMed ID: 18986024
    [No Abstract]   [Full Text] [Related]  

  • 37. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulatory anticipation of postmarket safety problems for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study.
    Zeitoun JD; Lefèvre JH; Downing NS; Bergeron H; Ross JS
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):687-94. PubMed ID: 26554874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The new EU legislation on pharmacovigilance and changing models for drug development.
    Callréus T
    Drug Saf; 2011 Jun; 34(6):529-30; author reply 530-1. PubMed ID: 21585224
    [No Abstract]   [Full Text] [Related]  

  • 40. Automated record linkage: a response to the commentary and letters to the editor.
    Shapiro S
    Clin Pharmacol Ther; 1989 Oct; 46(4):395-8. PubMed ID: 2791442
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.